Nectin-4 expression patterns and therapeutics in oncology.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Nectin-4, a transmembrane receptor, drives tumor cell migration, adhesion, and proliferation.
• Nectin-4 exhibits minimal expression in healthy tissues but is significantly overexpressed in various cancers, including breast, bladder, colorectal, gallbladder, gastric, and non-small cell lung cancers.

Purpose of the Study:

• To review nectin-4 expression and amplification in cancer.
• To evaluate nectin-4 as a potential response biomarker.
• To summarize clinical trials of nectin-4-targeting agents, including enfortumab vedotin.

Main Methods:

• Literature review of studies on nectin-4 expression in cancer.
• Analysis of clinical trial data for nectin-4-targeted therapies.
• Assessment of nectin-4's role as a predictive biomarker.

Main Results:

• Nectin-4 overexpression and amplification are observed across multiple cancer types.
• Enfortumab vedotin, an antibody-drug conjugate targeting nectin-4, is approved for advanced urothelial cancers.
• Several novel nectin-4-targeting agents are under investigation.

Conclusions:

• Nectin-4 is a promising therapeutic target and biomarker in oncology.
• Biomarker-driven strategies targeting nectin-4 show potential across diverse tumor types.
• Further investigation of nectin-4-directed therapies is crucial for advancing cancer treatment.